Nkarta Valuation

Is NKTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NKTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NKTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NKTX's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for NKTX?

Other financial metrics that can be useful for relative valuation.

NKTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-0.8x
PEG Ration/a

Price to Book Ratio vs Peers

How does NKTX's PB Ratio compare to its peers?

The above table shows the PB ratio for NKTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average3.3x
SLRN Acelyrin
0.7x-0.4%US$431.8m
CRBP Corbus Pharmaceuticals Holdings
5.8x-32.4%US$565.2m
TCRX TScan Therapeutics
3.9x-8.1%US$475.8m
IGMS IGM Biosciences
2.9x23.2%US$468.6m
NKTX Nkarta
0.9x-3.4%US$439.0m

Price-To-Book vs Peers: NKTX is good value based on its Price-To-Book Ratio (0.9x) compared to the peer average (3.3x).


Price to Earnings Ratio vs Industry

How does NKTX's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a24.7%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a24.7%
n/an/an/a
No more companies

Price-To-Book vs Industry: NKTX is good value based on its Price-To-Book Ratio (0.9x) compared to the US Biotechs industry average (2.1x).


Price to Book Ratio vs Fair Ratio

What is NKTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NKTX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NKTX's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NKTX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$6.23
US$19.29
+209.6%
24.0%US$25.00US$13.00n/a7
Jun ’25US$6.79
US$19.29
+184.0%
24.0%US$25.00US$13.00n/a7
May ’25US$7.49
US$19.25
+157.0%
21.1%US$25.00US$15.00n/a8
Apr ’25US$10.82
US$19.25
+77.9%
21.1%US$25.00US$15.00n/a8
Mar ’25US$12.84
US$16.00
+24.6%
32.9%US$25.00US$9.00n/a7
Feb ’25US$10.61
US$16.00
+50.8%
32.9%US$25.00US$9.00n/a7
Jan ’25US$6.60
US$14.86
+125.1%
32.3%US$25.00US$9.00n/a7
Dec ’24US$2.72
US$14.88
+446.9%
28.6%US$25.00US$10.00n/a8
Nov ’24US$1.91
US$15.38
+705.0%
26.0%US$25.00US$10.00n/a8
Oct ’24US$1.39
US$18.75
+1,248.9%
27.6%US$26.00US$13.00n/a8
Sep ’24US$1.77
US$19.29
+989.6%
27.5%US$26.00US$13.00n/a7
Aug ’24US$2.26
US$19.63
+768.4%
24.2%US$26.00US$13.00n/a8
Jul ’24US$2.19
US$19.63
+796.1%
24.2%US$26.00US$13.00n/a8
Jun ’24US$4.59
US$26.25
+471.9%
14.8%US$32.00US$18.00US$6.798
May ’24US$5.17
US$26.63
+415.0%
11.9%US$32.00US$21.00US$7.498
Apr ’24US$3.55
US$26.78
+654.3%
11.2%US$32.00US$21.00US$10.829
Mar ’24US$4.32
US$30.00
+594.4%
15.0%US$38.00US$25.00US$12.849
Feb ’24US$5.57
US$30.00
+438.6%
15.0%US$38.00US$25.00US$10.619
Jan ’24US$5.99
US$30.80
+414.2%
15.9%US$38.00US$25.00US$6.6010
Dec ’23US$8.37
US$36.27
+333.4%
41.0%US$81.00US$25.00US$2.7211
Nov ’23US$12.69
US$38.27
+201.6%
40.0%US$81.00US$25.00US$1.9111
Oct ’23US$13.16
US$40.67
+209.0%
39.2%US$81.00US$25.00US$1.399
Sep ’23US$14.55
US$40.67
+179.5%
39.2%US$81.00US$25.00US$1.779
Aug ’23US$12.46
US$41.80
+235.5%
39.7%US$81.00US$25.00US$2.2610
Jul ’23US$13.18
US$44.11
+234.7%
36.7%US$81.00US$25.00US$2.199
Jun ’23US$13.61
US$44.11
+224.1%
36.7%US$81.00US$25.00US$4.599

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.